Bhalla Narinder Pal 4

What Happened

• Narinder Bhalla, Chief Medical Officer of Lexeo Therapeutics (LXEO), was granted equity awards on 2026-02-13: 49,500 restricted stock units (RSUs) and a 297,000-share derivative award (reported as $0 cost). These are awards (code A) — not open-market purchases or sales — and will vest according to the schedules below. There was no cash paid by the reporting person at grant.

Key Details

• Transaction date reported: 2026-02-13; Form filed 2026-02-17. No late-filing flag is indicated in the Form 4.
• Awards: 49,500 RSUs (each converts to one share upon vesting) and a 297,000-share derivative award (appears to be an option/derivative grant).
• Price: $0.00 reported (typical for compensation grants).
• Shares owned after transaction: not disclosed in the filing.
• Vesting/footnotes:
  • RSUs (49,500): 25% vest on Feb 15, 2027, then 1/16th of the original grant vests on each standard quarterly vesting date thereafter, subject to continued service (Footnote F1/F2).
  • Derivative award (297,000): 25% of the underlying shares vest on Jan 20, 2027, then 1/48th vests monthly thereafter, subject to continuous service (Footnote F3).

Context

• These awards are standard equity compensation and do not represent an immediate market purchase or sale; they convert to shares or become exercisable only as they vest. Such grants are typically part of executive compensation and reflect expected future service rather than a direct bullish or bearish signal.